J Clin Oncol 2021 Oct 26
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
Abstract
Purpose
Definitive or postoperative chemoradiation (CRT) is curative for human papillomavirus-associated (HPV+) oropharynx cancer (OPC) but induces significant toxicity. As a deintensification strategy, we studied primary transoral surgery (TOS) and reduced postoperative radiation therapy (RT) in intermediate-risk HPV+ OPC.
Methods
E3311 is a phase II randomized trial of reduced- or standard-dose postoperative RT for resected stage III-IVa (American Joint Committee on Cancer-seventh edition) HPV+ OPC, determined by pathologic parameters. Primary goals were feasibility of prospective multi-institutional study of TOS for HPV+ OPC, and oncologic efficacy (2-year progression-free survival) of TOS and adjuvant therapy in intermediate-risk patients after resection. TOS plus 50 Gy was considered promising if the lower limit of the exact 90% binomial confidence intervals exceeded 85%. Quality of life and swallowing were measured by functional assessment of cancer therapy-head and neck and MD Anderson Dysphagia Index.
Results
Credentialed surgeons performed TOS for 495 patients. Eligible and treated patients were assigned as follows: arm A (low risk, n = 38) enrolled 11%, intermediate risk arms B (50 Gy, n = 100) or C (60 Gy, n = 108) randomly allocated 58%, and arm D (high risk, n = 113) enrolled 31%. With a median 35.2-month follow-up for 359 evaluable (eligible and treated) patients, 2-year progression-free survival Kaplan-Meier estimate is 96.9% (90% CI, 91.9 to 100) for arm A (observation), 94.9% (90% CI, 91.3 to 98.6]) for arm B (50 Gy), 96.0% (90% CI, 92.8 to 99.3) for arm C (60 Gy), and 90.7% (90% CI, 86.2 to 95.4) for arm D (66 Gy plus weekly cisplatin). Treatment arm distribution and oncologic outcome for ineligible or step 2 untreated patients (n = 136) mirrored the 359 evaluable patients. Exploratory comparison of functional assessment of cancer therapy-head and neck total scores between arms B and C is presented.
Conclusion
Primary TOS and reduced postoperative RT result in outstanding oncologic outcome and favorable functional outcomes in intermediate-risk HPV+ OPC.
Related Questions
What would be the targets and dosing for a patient with p16+ unilateral neck disease and a small basaloid SCC of the BOT found after diagnostic tonsillectomy and BOT resection?
While detailed, often these questions are not detailed enough, and so I try to generalize and read between the lines to think what the specific question might be. The nuances are: Is the question p16+/basaloid SCC different from HPV+? The short answer is no. What is a diagnostic tonsillectomy and BO...
What role do you see for functional imaging in selecting patients with HPV-associated oropharyngeal cancer for radiation dose de-escalation?
This study, led by Dr. @Dr. First Last, is unique in using F-MISO PET to select patients for a notably aggressive de-escalation plan, to a 30 Gy total dose for responding patients. We need to wait for long-term results before accepting it in the clinic, notwithstanding that F-MISO is not widely avai...
How would the updated results of ECOG 3311 influence your adjuvant RT recommendations for HPV+ OPSCC?
This question refers to this manuscript (Burtness et al., PMID 40493877), which is a 4.5-year follow-up of ECOG E3311.The results broadly mirror those seen in previous reports. The most notable novel finding reported is that among patients with low-risk features (who did not get any adjuvant RT), th...
For a patient s/p TORS with indications for adjuvant radiation, how does your management change with persistently elevated ctHPVDNA?
At this time, it's a bit challenging to make any meaningful treatment changes based on positive post-operative ctHPVDNA. But it certainly raises my suspicion - I would take a close look at the CT simulation for any potential grossly positive nodes (especially a retropharyngeal node that may not have...
How would you manage the contralateral neck and adjacent structures for a glossotonsillar or glossopharyngeal sulcus primary cancer if well lateralized?
The glossopharyngeal and glossotonsilar sulci are the grooves between the lateral oropharyngeal wall or the tonsil and the base of the tongue, representing a very lateral OPC location that does not require contralateral neck RT. The main neck nodes at risk are II and III. In the absence of significa...
What dose are you routinely using for adjuvant RT for intermediate risk p16+ SCC of the OPX s/p TORS?
It's still just a phase II trial. Even the authors state in the introduction that their primary objectives were to demonstrate the feasibility of a prospective multi-institutional study of TOS for HPV+ OPC followed by risk-adjusted adjuvant therapy and that a planned phase III trial is in developmen...
Do you take the primary dissected site for postoperative oral cavity cancers with bony invasion to 66 Gy?
Dr. @Dr. First Last correctly addresses the nuanced indication for PORT due to bone involvement.60 Gy is embedded in the PORT culture. For at least 30 years, RTOG trials have recommended 60 Gy with an optional boost to 66 Gy for PORT, though the EORTC trial (Bernier et al., PMID 15128894) went to 66...
In what clinical situations do you order NavDx?
At MSKCC, we largely use NavDx as part of our post-operative de-escalation trial in which NavDx is checked pre and post surgery to help select patients for de-escalation. If NavDx becomes undetectable after surgery: In patients with pathologic risk factors that warrant adjuvant RT, patients undergo...
When, if ever, would you consider dose de-escalation for HPV-associated non-oropharyngeal HNSCC?
This is a very complex question, as the issues of dose, and de-escalation can be difficult to sum up in an hour lecture let alone a Mednet query. Personally, for me, efforts to lessen volume and doses to subclinical disease are a bit more interesting.Quoting Cmelak et al., PMID 34043410 (2021) in an...
What adverse features would prompt you to give post-TORS radiation therapy to completely resected early stage (T0-2) p16+ tonsillar cancer?
I would base my recommendation on the standard and conventional indications for PORT, which in this case of an early-stage primary tumor with negative margins, would comprise the presence of PNI, LVI, close (<3-5 mm) margins, single node >3 cm, or multiple positive nodes. I assume there is no extrac...
Is it appropriate to dose de-escalate in low risk HPV+ SCC of the oropharynx outside of a clinical trial setting?
I am going to write specifically on de-escalating HPV-OPSCC in the adjuvant setting first, important caveats for adjuvant de-escalation, and then about the general philosophy on de-escalation in clinical trials.Concerning adjuvant treatment, after careful consent, we are de-escalating patients with ...